| Muscular Dystrophy, Duchenne
Amondys 45 vs Viltepso
Side-by-side clinical, coverage, and cost comparison for muscular dystrophy, duchenne.Deep comparison between: Amondys 45 vs Viltepso with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsViltepso has a higher rate of injection site reactions vs Amondys 45 based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Viltepso but not Amondys 45, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Amondys 45
Viltepso
At A Glance
IV infusion
Once weekly
Antisense oligonucleotide (exon 45 skipper)
IV infusion
Once weekly
Antisense oligonucleotide (PMO)
Indications
- Muscular Dystrophy, Duchenne
- Muscular Dystrophy, Duchenne
Dosing
Muscular Dystrophy, Duchenne 30 mg/kg once weekly as a 35 to 60-minute IV infusion via an in-line 0.2 micron filter.
Muscular Dystrophy, Duchenne 80 mg/kg once weekly as a 60-minute IV infusion; serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting.
Contraindications
- Known serious hypersensitivity to casimersen or to any of the inactive ingredients in AMONDYS 45
—
Adverse Reactions
Most common (>=20%) Upper respiratory tract infections, cough, pyrexia, headache, arthralgia, oropharyngeal pain
Serious Hypersensitivity reactions including angioedema and anaphylaxis
Postmarketing Infusion-related reactions including rash, headache, cough, abdominal pain, and vomiting; hypersensitivity reactions including angioedema and anaphylaxis
Most common (>=15%) Upper respiratory tract infection, injection site reaction, cough, pyrexia
Common (>=10%) Contusion, arthralgia, diarrhea, vomiting, abdominal pain, ejection fraction decreased, urticaria
Pharmacology
Casimersen is an antisense oligonucleotide (phosphorodiamidate morpholino oligomer subclass) that binds to exon 45 of dystrophin pre-mRNA, causing exon 45 skipping and production of an internally truncated dystrophin protein in patients with DMD mutations amenable to exon 45 skipping.
Viltolarsen is an antisense oligonucleotide (phosphorodiamidate morpholino oligomer subclass) that binds to exon 53 of dystrophin pre-mRNA, causing exon 53 skipping during mRNA processing and enabling production of an internally truncated dystrophin protein in patients with DMD gene mutations amenable to exon 53 skipping.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Amondys 45
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Viltepso
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Amondys 45
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Viltepso
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Amondys 45
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Viltepso
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Duchenne Muscular Dystrophy
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Duchenne Muscular Dystrophy
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Amondys 45View full Amondys 45 profile
ViltepsoView full Viltepso profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.